We are very pleased to announce the 1st Virtual Canadian Multidisciplinary Hepatocellular Carcinoma Conference 2021 (CMHCC) will be taking place on Friday October 29, 2021,
from 10 am to 4 pm EST. VIEW RECORDED SESSIONS
Our objective for the 1st Canadian Multidisciplinary Hepatocellular Carcinoma Conference is to provide high quality education that meets the learning needs of our colleagues. Medical oncologists, radiation oncologist, interventional radiologists, surgical oncologist, hepatologists, internists, as well as residents, nurse practitioners and pharmacists, with an interest in HCC, will gather virtually to share best practices and review challenging cases with multidisciplinary panels.
This informative conference provides a unique opportunity for attendees to participate in presentations from international experts in the ﬁeld of Multidisciplinary Hepatocellular Carcinoma. The scope of this meeting will highlight both recent research ﬁndings elucidating the pathophysiology of these diverse diseases, as well as changes in therapeutic advances that have had a large impact in the management of our patients.
We look forward to your participation in this exciting virtual conference which promises to be a valuable educational experience.
Rachel Goodwin, MSc, MD, FRCPC, Assistant Professor of Medicine, University of Ottawa
Jennifer Knox, MSc, MD, FRCPC, Professor, Dept. of Medicine, University of Toronto
Brandon Meyers, MSc, MD, FRCPC, Associate Professor, McMaster University
Vincent Tam, MD, FRCPC, Clinical Associate Professor, University of Calgary
CMHCC Planning Committee
Kelly Burak, MD, MSc (Epid), FRCPC, Professor of Medicine, University of Calgary
Laura Dawson, MD, FRCPC, FASTRO, Professor, University of Toronto
David Liu, MD, FRCP(C), FSIR, ABR(D), CAQ(IR),Clinical Professor, University of British Columbia
Gonzalo Sapisochin, MD, PhD, MSc, Associate Professor of Surgery, University of Toronto
-Establish principles of non-surgical techniques for curative intent management
-Review the evidence of liver transplant, and aspects of patient selection
-Examine the data on surgical management of early stage HCC a
Intermediate Stage Disease
-Review the evidence available in defining what is TACE refractory disease and
what other options are
-Examine the data on systemic therapy in intermediate stage HCC
-Evaluate both the strengths and limitations of the BCLC staging system
Advanced Stage Disease
-Review the data on biomarker development in the management of HCC
-Review the existing data on current stem of therapy for advanced HCC as well as future systemic therapy options
-Create a form of open discussion and cross disciplinary knowledge translation
- Medical Oncologists, Radiation Oncologists, Interventional Radiologists, Surgical Oncologists Hepatologists, Internists, as well as Residents, Nurse Practitioners and Pharmacists, with an interest in HCC
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.
This activity was approved by the Canadian Association of Medical Oncologists for a maximum of 5 hours.